Ola Dale
Background and activities
Trained in anestesiology and clinical pharmacology. Worked at St Olavs Hospitla and Faculty of Medicine, NTNU, Trondheim since 1978. had four research sabbaticals abroad
https://backends.it.ntnu.no/syndicator-web/public/files/ff35c445-dd31-35bd-b36a-379921f2848d
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
Journal publications
- (2022) Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial. Addiction.
- (2021) A Clinical Description of Chronic Pain in a General Population Using ICD-10 and ICD-11 (The HUNT Pain Examination Study). Journal of Pain. vol. 23 (2).
- (2021) The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. European Journal of Clinical Pharmacology.
- (2020) NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open. vol. 10:e041556 (11).
- (2020) Prehospital naloxone administration – what influences choice of dose and route of administration?. BMC Emergency Medicine. vol. 20.
- (2019) European survey on national training activities in clinical research. Trials. vol. 20.
- (2019) Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. Addiction. vol. 114 (5).
- (2019) Take-home naloxone for the emergency interim management of opioid overdose: The public health application of an emergency medicine. Drugs.
- (2019) Naloksonnesespray – biotilgjengelighet og opptaksmønster i en fase 1-studie. Tidsskrift for Den norske legeforening. vol. 139 (13).
- (2018) Development and course of chronic pain over 4 years in the general population: The HUNT pain study. European Journal of Pain. vol. 22 (9).
- (2018) Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility. Substance Abuse.
- (2018) Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. European Journal of Clinical Pharmacology. vol. 74 (7).
- (2018) Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil. European Journal of Clinical Pharmacology. vol. 74 (12).
- (2017) International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. Drug and Alcohol Review. vol. 37 (2).
- (2017) Opioid education programs and nasal naloxone rescue kits in Europe. Toxicology Letters. vol. 280.
- (2017) Pharmacokinetics of a new, nasal formulation of naloxone. European Journal of Clinical Pharmacology. vol. 73 (5).
- (2016) Ethical issues and stakeholders matter. Addiction. vol. 111 (4).
- (2016) The rare Arg181Cys mutation in the μ opioid receptor can abolish opioid responses. Acta Anaesthesiologica Scandinavica. vol. 60 (8).
- (2015) Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLOS ONE. vol. 10:0137179 (9).
- (2015) Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids. BMC Public Health. vol. 15.